The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.

New TAVR data on SAPT vs. DAPT and prosthesis-patient mismatch among women were some of the many highlights of the conference's opening day.

Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate. 

The FDA has approved the balloon-expandable Sapien 3 TAVR platform from Edwards Lifesciences for treating asymptomatic severe aortic stenosis. This is the first time the agency has approved any TAVR technology to be used in asymptomatic patients. 

The new resource was built to help care teams plan for ascending aorta and aortic root surgeries.

Robotic and traditional mitral valve repair surgeries are mostly associated with similar outcomes when treating elderly patients. In some ways, however, robotic procedures may be preferred. 

Consulting fees and other vendor payments do not appear to be directly influencing U.S. physicians to implant more Watchman devices. Researcher Alexander Kolomaya, MD, discussed his team's findings on this topic.

Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways.